Mary Wilson
Well-known member
21 October 2020
https://doi.org/10.7326/M20-4986
Ashley Kieran Clift, MA, MBBS, Carol A.C. Coupland, PhD, Ruth H. Keogh, DPhil, Harry Hemingway, PhD, Julia Hippisley-Cox, MD
Down syndrome features on neither the U.K. shielding list nor the U.S. Centers for Disease Control and Prevention list of groups at “increased risk.” However, it is associated with immune dysfunction, congenital heart disease, and pulmonary pathology and, given its prevalence, may be a relevant albeit unconfirmed risk factor for severe COVID-19 (1).
Objective: To evaluate Down syndrome as a risk factor for death from COVID-19 through a comprehensive analysis of individual-level data in a cohort study of 8.26 million adults (aged >19 years), as part of a wider COVID-19 risk prediction project commissioned by the U.K. government (2).
https://www.acpjournals.org/doi/10.7326/M20-4986#.X5CIOEBaGHo.twitter
https://doi.org/10.7326/M20-4986
Ashley Kieran Clift, MA, MBBS, Carol A.C. Coupland, PhD, Ruth H. Keogh, DPhil, Harry Hemingway, PhD, Julia Hippisley-Cox, MD
Down syndrome features on neither the U.K. shielding list nor the U.S. Centers for Disease Control and Prevention list of groups at “increased risk.” However, it is associated with immune dysfunction, congenital heart disease, and pulmonary pathology and, given its prevalence, may be a relevant albeit unconfirmed risk factor for severe COVID-19 (1).
Objective: To evaluate Down syndrome as a risk factor for death from COVID-19 through a comprehensive analysis of individual-level data in a cohort study of 8.26 million adults (aged >19 years), as part of a wider COVID-19 risk prediction project commissioned by the U.K. government (2).
https://www.acpjournals.org/doi/10.7326/M20-4986#.X5CIOEBaGHo.twitter